









Markets
/
Stocks
/
nasdaq-gnpx
/

Genprex Inc

GNPX

2.200USD

+0.240+12.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.21MMarket Cap

0.04P/E TTM



Genprex Inc

2.200

+0.240+12.24%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Genprex Inc

Currency: USD Updated: 2026-02-06

Key Insights

Genprex Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 229 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Genprex Inc's Score

Industry at a Glance

Industry Ranking

229 / 392

Overall Ranking

488 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Genprex Inc Highlights

StrengthsRisks

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Overvalued

The company’s latest PE is 0.04, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.83K shares, decreasing 36.31% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

7.500

Target Price

+3230.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Genprex Inc is 6.82, ranking 205 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Genprex Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Genprex Inc is 6.14, ranking 327 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.04, which is 33915.54% below the recent high of 13.57 and 9110.78% above the recent low of -3.60.

Score

Industry at a Glance

Previous score

6.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 229/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Genprex Inc. The Biotechnology & Medical Research industry's average is 8.05. The average price target is 7.50, with a high of 7.50 and a low of 7.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Genprex Inc is 5.12, ranking 329 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.21 and the support level at 1.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.13

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Sell

RSI(14)

44.224

Neutral

STOCH(KDJ)(9,3,3)

19.215

Neutral

ATR(14)

0.366

Low Volatility

CCI(14)

-103.162

Sell

Williams %R

76.562

Sell

TRIX(12,20)

-0.031

Sell

StochRSI(14)

59.977

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.252

Sell

MA10

2.339

Sell

MA20

2.559

Sell

MA50

2.500

Sell

MA100

5.867

Sell

MA200

9.278

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Genprex Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 0.85%, representing a quarter-over-quarter decrease of 41.38%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Confer (Ryan M.)

45.66K

+6828.53%

Berger (Mark Stanley)

28.86K

+7938.72%

Intracoastal Capital, L.L.C.

16.96K

Longnecker (Brent M)

9.17K

+5172.41%

Moreno (Toscano Jose Antonio)

9.16K

+5732.48%

Wilson (William R. Jr)

9.16K

+5732.48%

Susquehanna International Group, LLP

6.80K

+11.71%

Jane Street Capital, L.L.C.

4.10K

Geode Capital Management, L.L.C.

3.28K

+118.15%

Schiketanz Capital Advisors GmbH

2.31K

+50.98%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Genprex Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is -0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Genprex Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.